| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.37B | 1.41B | 1.37B | 990.04M | 997.79M | 794.28M |
| Gross Profit | 573.00M | 611.30M | 621.13M | 434.70M | 448.67M | 349.48M |
| EBITDA | 316.81M | 335.37M | 434.82M | 267.87M | 304.65M | 225.18M |
| Net Income | 172.27M | 195.08M | 228.91M | 187.75M | 161.75M | 124.14M |
Balance Sheet | ||||||
| Total Assets | 3.00B | 2.88B | 2.92B | 2.72B | 2.51B | 1.09B |
| Cash, Cash Equivalents and Short-Term Investments | 1.47B | 1.54B | 1.55B | 1.68B | 1.78B | 413.25M |
| Total Debt | 253.76M | 218.01M | 200.80M | 196.16M | 178.65M | 142.36M |
| Total Liabilities | 638.53M | 554.76M | 544.38M | 424.68M | 378.11M | 325.48M |
| Stockholders Equity | 2.35B | 2.32B | 2.36B | 2.27B | 2.11B | 737.25M |
Cash Flow | ||||||
| Free Cash Flow | 279.75M | 354.36M | 286.02M | 148.29M | 189.18M | 196.16M |
| Operating Cash Flow | 361.45M | 354.36M | 372.57M | 273.41M | 249.39M | 248.75M |
| Investing Cash Flow | -315.07M | 245.36M | -654.10M | -464.77M | -578.51M | -35.45M |
| Financing Cash Flow | -160.85M | -292.30M | -204.01M | -165.43M | 1.19B | -39.61M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | HK$601.91M | 7.29 | 5.33% | 9.14% | 0.47% | 50.46% | |
69 Neutral | HK$927.34M | 12.28 | 6.35% | 1.99% | -1.61% | -27.39% | |
68 Neutral | HK$1.87B | 9.87 | 7.31% | 9.29% | -3.19% | -20.30% | |
66 Neutral | HK$1.57B | 5.42 | 20.47% | 4.37% | -3.56% | -17.45% | |
52 Neutral | HK$1.66B | -11.56 | -4.66% | 0.49% | -0.55% | 45.36% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | HK$2.01B | -17.19 | -6.41% | 1.20% | 2.05% | -285.88% |
Chaoju Eye Care Holdings Ltd. has announced its intention to conduct an on-market share repurchase of up to HK$50 million, demonstrating confidence in its business outlook and aiming to create value for its shareholders. This move, subject to market conditions and regulatory compliance, reflects the company’s strategic decision to utilize its financial resources effectively while maintaining a solid financial position.
The most recent analyst rating on (HK:2219) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on Chaoju Eye Care Holdings Ltd. stock, see the HK:2219 Stock Forecast page.